Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Convertible Debt (2022)

bioAffinity Technologies (BIAF) has disclosed Convertible Debt for 1 consecutive years, with $325000.0 as the latest value for Q4 2022.

  • Quarterly Convertible Debt changed N/A to $325000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $325000.0 through Dec 2022, changed N/A year-over-year, with the annual reading at $325000.0 for FY2022, N/A changed from the prior year.
  • Convertible Debt for Q4 2022 was $325000.0 at bioAffinity Technologies, down from $2.6 million in the prior quarter.
  • The five-year high for Convertible Debt was $2.6 million in Q1 2022, with the low at $325000.0 in Q4 2022.